Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that it has received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its Covid-19 vaccine (mRNA-1273) in young children ages 6 months through 5 years of age at a dose level of 25
